All Clinical Trials
Filter by Category
- All Clinical Trials
- Clinical Studies
- Treatment-Naive
- Treatment-Experienced
- Switch/Simplification
- Dual Therapy
- Monotherapy
- PREP
- PEP
- Acute HIV
- Resistance/Virological Failure
- Pharmacology
- General Pharmacology
- Adverse Effects
- Drug Interactions
- Pregnancy/Women
- Pediatrics
- Review
Common Title01A2B Non-Industry
Official Title Reversibility of Mitochondrial Toxicity in HIV Lipoatrophy
Phase Phase II
ClinicalTrials.gov NCT00119379
Treatments
Stavudine![Stavudine Zerit](https://cdn.hiv.uw.edu/css/images/drugs/11.png)
, ![Stavudine Zerit](https://cdn.hiv.uw.edu/css/images/drugs/11.png)
Stavudine
Tradename:ZeritOther Names:d4TClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)Tenofovir DF![Tenofovir DF Viread](https://cdn.hiv.uw.edu/css/images/drugs/31.png)
![Tenofovir DF Viread](https://cdn.hiv.uw.edu/css/images/drugs/31.png)
Tenofovir DF
Tradename:VireadOther Names:TDF, tenofovir disoproxil fumarateClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)Categories PharmacologySwitch/SimplificationAdverse Effects
Funding
Non-IndustryNational Institute of Allergy and Infectious Diseases (NIAID)
References
- McComsey GA, O'Riordan M, Choi J, et al. Mitochondrial function, inflammation, fat and bone in HIV lipoatrophy: randomized study of uridine supplementation or switch to tenofovir. Antivir Ther. 2012;17:347-53.
Common Title903E Industry
Official Title A Phase 3, Randomized, Double-Blind, Multicenter Study of the Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavirenz.(Extension)
Phase Phase III
ClinicalTrials.gov NCT00158821
Treatments
Stavudine![Stavudine Zerit](https://cdn.hiv.uw.edu/css/images/drugs/11.png)
, ![Stavudine Zerit](https://cdn.hiv.uw.edu/css/images/drugs/11.png)
Stavudine
Tradename:ZeritOther Names:d4TClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)Efavirenz![Efavirenz Sustiva](https://cdn.hiv.uw.edu/css/images/drugs/26.png)
, ![Efavirenz Sustiva](https://cdn.hiv.uw.edu/css/images/drugs/26.png)
Efavirenz
Tradename:SustivaOther Names:EFVClass:Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)Tenofovir DF![Tenofovir DF Viread](https://cdn.hiv.uw.edu/css/images/drugs/31.png)
![Tenofovir DF Viread](https://cdn.hiv.uw.edu/css/images/drugs/31.png)
Tenofovir DF
Tradename:VireadOther Names:TDF, tenofovir disoproxil fumarateClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)Categories PharmacologySwitch/SimplificationAdverse Effects
Funding
IndustryGilead Sciences
References
- Madruga JR, Cassetti I, Suleiman JM, et al. The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy. HIV Clin Trials. 2007;8:381-90.
Official Title A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Phase Phase II
ClinicalTrials.gov NCT01400412
Treatments
Maraviroc![Maraviroc Selzentry](https://cdn.hiv.uw.edu/css/images/drugs/17.png)
, ![Maraviroc Selzentry](https://cdn.hiv.uw.edu/css/images/drugs/17.png)
Maraviroc
Tradename:SelzentryOther Names:MVCClass:Entry InhibitorsTenofovir DF![Tenofovir DF Viread](https://cdn.hiv.uw.edu/css/images/drugs/31.png)
![Tenofovir DF Viread](https://cdn.hiv.uw.edu/css/images/drugs/31.png)
Tenofovir DF
Tradename:VireadOther Names:TDF, tenofovir disoproxil fumarateClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)Categories PharmacologyTreatment-NaiveAdverse Effects
Funding
Non-IndustryNational Institute of Allergy and Infectious Diseases (NIAID)
References
- Taiwo BO, Chan ES, Fichtenbaum CJ, et al. Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study. Clin Infect Dis. 2015;61:1179-88.
Official Title A Phase III, Randomized, Open-Label Comparison of Lopinavir/Ritonavir Plus Efavirenz Versus Lopinavir/Ritonavir Plus 2 NRTIs Versus Efavirenz Plus 2 NRTIs as Initial Therapy for HIV-1 Infection
Phase Phase III
ClinicalTrials.gov NCT00050895
Treatments
Stavudine![Stavudine Zerit](https://cdn.hiv.uw.edu/css/images/drugs/11.png)
, ![Stavudine Zerit](https://cdn.hiv.uw.edu/css/images/drugs/11.png)
Stavudine
Tradename:ZeritOther Names:d4TClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)Zidovudine![Zidovudine Retrovir](https://cdn.hiv.uw.edu/css/images/drugs/13.png)
, ![Zidovudine Retrovir](https://cdn.hiv.uw.edu/css/images/drugs/13.png)
Zidovudine
Tradename:RetrovirOther Names:ZDVClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)Lopinavir-Ritonavir![Lopinavir-Ritonavir Kaletra](https://cdn.hiv.uw.edu/css/images/drugs/20.png)
, ![Lopinavir-Ritonavir Kaletra](https://cdn.hiv.uw.edu/css/images/drugs/20.png)
Lopinavir-Ritonavir
Tradename:KaletraOther Names:LPV-RTVClass:Protease Inhibitors (PI)Efavirenz![Efavirenz Sustiva](https://cdn.hiv.uw.edu/css/images/drugs/26.png)
, ![Efavirenz Sustiva](https://cdn.hiv.uw.edu/css/images/drugs/26.png)
Efavirenz
Tradename:SustivaOther Names:EFVClass:Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)Tenofovir DF![Tenofovir DF Viread](https://cdn.hiv.uw.edu/css/images/drugs/31.png)
![Tenofovir DF Viread](https://cdn.hiv.uw.edu/css/images/drugs/31.png)
Tenofovir DF
Tradename:VireadOther Names:TDF, tenofovir disoproxil fumarateClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)Categories PharmacologyTreatment-NaiveAdverse EffectsDual Therapy
Funding
Non-IndustryNational Institute of Allergy and Infectious Diseases (NIAID)
References
- Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS. 2009;23:1109-18.
- Hulgan T, Haubrich R, Riddler SA, et al. European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142. AIDS. 2011;25:37-47.
- Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358:2095-106.
Official Title Study of the Safety and Efficacy of Daily Tenofovir to Prevent HIV Infection Among Injection Drug Users in Bangkok, Thailand
Phase Phase III
ClinicalTrials.gov NCT00119106
Treatments
Tenofovir DF![Tenofovir DF Viread](https://cdn.hiv.uw.edu/css/images/drugs/31.png)
![Tenofovir DF Viread](https://cdn.hiv.uw.edu/css/images/drugs/31.png)
Tenofovir DF
Tradename:VireadOther Names:TDF, tenofovir disoproxil fumarateClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)Categories PREPPharmacologyAdverse Effects
Funding
Non-IndustryCenters for Disease Control and Prevention and the Bangkok Metropolitan Administration
References
- Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381:2083-90.
- Martin M, Vanichseni S, Suntharasamai P, et al. Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir Study, Thailand. PLoS One. 2011;6:e25127.
- Martin M, Vanichseni S, Suntharasamai P, et al. Renal function of participants in the Bangkok tenofovir study--Thailand, 2005-2012. Clin Infect Dis. 2014;59:716-24.
- Martin M, Vanichseni S, Suntharasamai P, et al. The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs. AIDS. 2015;29:819-24.
Common TitleGS-98-902 Industry
Official Title A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Antiviral Activity of the Addition of PMPA Prodrug to Combination Antiretroviral Regimens in Treatment-Experienced HIV-Infected Patients
Phase Phase II
ClinicalTrials.gov NCT00002415
Treatments
Tenofovir DF![Tenofovir DF Viread](https://cdn.hiv.uw.edu/css/images/drugs/31.png)
![Tenofovir DF Viread](https://cdn.hiv.uw.edu/css/images/drugs/31.png)
Tenofovir DF
Tradename:VireadOther Names:TDF, tenofovir disoproxil fumarateClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)Categories Resistance/Virological FailureTreatment-Experienced
Funding
IndustryGilead Sciences
References
- Margot NA, Isaacson E, McGowan I, Cheng A, Miller MD. Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses. J Acquir Immune Defic Syndr. 2003;33:15-21.
- Margot NA, Isaacson E, McGowan I, Cheng AK, Schooley RT, Miller MD. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS. 2002;16:1227-35.
Common TitleGS-99-907 Industry
Official Title A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of Tenofovir Disoproxil Fumarate in Combination With Other Antiretroviral Agents for the Treatment of HIV-1 Infected Patients
Phase Phase III
ClinicalTrials.gov NCT00002450
Treatments
Tenofovir DF![Tenofovir DF Viread](https://cdn.hiv.uw.edu/css/images/drugs/31.png)
![Tenofovir DF Viread](https://cdn.hiv.uw.edu/css/images/drugs/31.png)
Tenofovir DF
Tradename:VireadOther Names:TDF, tenofovir disoproxil fumarateClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)Categories Resistance/Virological FailureTreatment-Experienced
Funding
IndustryGilead Sciences
References
- McColl DJ, Margot NA, Wulfsohn M, Coakley DF, Cheng AK, Miller MD. Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate. J Acquir Immune Defic Syndr. 2004;37:1340-50.
- Squires K, Pozniak AL, Pierone G Jr, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med. 2003;139:313-20.
Official Title Parallel Comparison of Tenofovir and Emtricitabine/Tenofovir Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples
Phase Phase III
ClinicalTrials.gov NCT00557245
Treatments
Tenofovir DF![Tenofovir DF Viread](https://cdn.hiv.uw.edu/css/images/drugs/31.png)
, ![Tenofovir DF Viread](https://cdn.hiv.uw.edu/css/images/drugs/31.png)
Tenofovir DF
Tradename:VireadOther Names:TDF, tenofovir disoproxil fumarateClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)Tenofovir DF-Emtricitabine![Tenofovir DF-Emtricitabine Truvada and Multiple Generics](https://cdn.hiv.uw.edu/css/images/drugs/35.png)
![Tenofovir DF-Emtricitabine Truvada and Multiple Generics](https://cdn.hiv.uw.edu/css/images/drugs/35.png)
Tenofovir DF-Emtricitabine
Tradename:Truvada and Multiple GenericsOther Names:TDF-FTC, Tenofovir disoproxil fumarate-EmtricitabineClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)Categories PREPPregnancy/Women
Funding
Non-IndustryBill & Melinda Gates Foundation
References
- Baeten JM, Donnell D, Mugo NR, et al. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. Lancet Infect Dis. 2014;14:1055-64.
- Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399-410.
- Celum C, Morrow RA, Donnell D, et al. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial. Ann Intern Med. 2014;161:11-9.
- Mugo NR, Hong T, Celum C, et al. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial. JAMA. 2014;312:362-71.
Common TitlePREPARE Non-Industry
Official Title A Randomized, Controlled, Open-Label, 48-Week Study of Continuing Successfully Suppressive Treatment in HIV-1 Infected Adults With First-Line Twice-Daily Zidovudine and Lamivudine-Based Regimens Versus Pro-actively Replacing of Zidovudine and Lamivudine by Once-Daily Emtricitabine and Tenofovir Disoproxil Fumarate to Prevent Progression of or Reverse Peripheral Lipoatrophy.
Phase Phase IV
ClinicalTrials.gov NCT00389194
Treatments
Tenofovir DF![Tenofovir DF Viread](https://cdn.hiv.uw.edu/css/images/drugs/31.png)
![Tenofovir DF Viread](https://cdn.hiv.uw.edu/css/images/drugs/31.png)
Tenofovir DF
Tradename:VireadOther Names:TDF, tenofovir disoproxil fumarateClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)Categories PharmacologyTreatment-ExperiencedSwitch/SimplificationAdverse Effects
Funding
Non-IndustryInternational Antiviral Therapy Evaluation Center
References
- Cotter AG, Vrouenraets SM, Brady JJ, et al. Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study. J Clin Endocrinol Metab. 2013;98:1659-66.
Common TitleRAVE Industry
Official Title A Phase II, Open-Label, Multicentre, Randomised, Comparator Study of Substitution With Tenofovir or Abacavir in HIV-1 Infected Individuals, With a Viral Load < 50 Copies/mL, Receiving a Thymidine Analogue (Zidovudine or Stavudine) as Part of Their Highly Active Antiretroviral Therapy (HAART)
Phase Phase II
ClinicalTrials.gov NCT00647946
Treatments
Abacavir![Abacavir Ziagen](https://cdn.hiv.uw.edu/css/images/drugs/10.png)
, ![Abacavir Ziagen](https://cdn.hiv.uw.edu/css/images/drugs/10.png)
Abacavir
Tradename:ZiagenOther Names:ABCClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)Tenofovir DF![Tenofovir DF Viread](https://cdn.hiv.uw.edu/css/images/drugs/31.png)
![Tenofovir DF Viread](https://cdn.hiv.uw.edu/css/images/drugs/31.png)
Tenofovir DF
Tradename:VireadOther Names:TDF, tenofovir disoproxil fumarateClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)Categories PharmacologyTreatment-ExperiencedSwitch/SimplificationAdverse Effects
Funding
IndustryGilead Sciences
References
- Moyle GJ, Sabin CA, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006;20:2043-50.
Common TitleSNAP Industry
Official Title SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial Function
ClinicalTrials.gov NCT00225082
Treatments
Stavudine![Stavudine Zerit](https://cdn.hiv.uw.edu/css/images/drugs/11.png)
, ![Stavudine Zerit](https://cdn.hiv.uw.edu/css/images/drugs/11.png)
Stavudine
Tradename:ZeritOther Names:d4TClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)Tenofovir DF![Tenofovir DF Viread](https://cdn.hiv.uw.edu/css/images/drugs/31.png)
![Tenofovir DF Viread](https://cdn.hiv.uw.edu/css/images/drugs/31.png)
Tenofovir DF
Tradename:VireadOther Names:TDF, tenofovir disoproxil fumarateClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)Categories PharmacologyTreatment-ExperiencedSwitch/SimplificationAdverse Effects
Funding
IndustryAbbott
References
- Gerschenson M, Kim C, Berzins B, et al. Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen. J Antimicrob Chemother. 2009;63:1244-50.
Official Title Phase 2B Safety and Effectiveness Study of Tenofovir 1% Gel, Tenofovir Disproxil Fumarate Tablet and Emtricitabine/Tenofovir Disoproxil Fumarate Tablet for the Prevention of HIV Infection in Women
Phase Phase IIB
ClinicalTrials.gov NCT00705679
Treatments
Tenofovir DF![Tenofovir DF Viread](https://cdn.hiv.uw.edu/css/images/drugs/31.png)
, ![Tenofovir DF Viread](https://cdn.hiv.uw.edu/css/images/drugs/31.png)
Tenofovir DF
Tradename:VireadOther Names:TDF, tenofovir disoproxil fumarateClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)Tenofovir DF-Emtricitabine![Tenofovir DF-Emtricitabine Truvada and Multiple Generics](https://cdn.hiv.uw.edu/css/images/drugs/35.png)
![Tenofovir DF-Emtricitabine Truvada and Multiple Generics](https://cdn.hiv.uw.edu/css/images/drugs/35.png)
Tenofovir DF-Emtricitabine
Tradename:Truvada and Multiple GenericsOther Names:TDF-FTC, Tenofovir disoproxil fumarate-EmtricitabineClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)Categories PREP
Funding
Non-IndustryNational Institute of Allergy and Infectious Diseases (NIAID)
References
- Dai JY, Hendrix CW, Richardson BA, et al. Pharmacological Measures of Treatment Adherence and Risk of HIV Infection in the VOICE Study. J Infect Dis. 2016;213:335-42.
- Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372:509-18.
- Moodley J, Naidoo S, Moodley J, Ramjee G. Sharing of Investigational Drug Among Participants in the Voice Trial. AIDS Behav. 2016;20:2709-2714.
- Noguchi LM, Richardson BA, Baeten JM, et al. Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study. Lancet HIV. 2015;2:e279-87.
- van der Straten A, Brown ER, Marrazzo JM, et al. Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study. J Int AIDS Soc. 2016;19:20642.